312 related articles for article (PubMed ID: 35619895)
1. Advances in Renal Cell Carcinoma Drug Resistance Models.
Xiang Y; Zheng G; Zhong J; Sheng J; Qin H
Front Oncol; 2022; 12():870396. PubMed ID: 35619895
[TBL] [Abstract][Full Text] [Related]
2. A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies.
Gürgen D; Becker M; Dahlmann M; Flechsig S; Schaeffeler E; Büttner FA; Schmees C; Bohnert R; Bedke J; Schwab M; Wendler JJ; Schostak M; Jandrig B; Walther W; Hoffmann J
Front Oncol; 2022; 12():889789. PubMed ID: 35800063
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 induces drug resistance in renal cell carcinoma.
Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
[TBL] [Abstract][Full Text] [Related]
5. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
6. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
7. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
8. Current management of renal cell carcinoma and targeted therapy.
Canda AE; Kirkali Z
Urol J; 2006; 3(1):1-14. PubMed ID: 17590846
[TBL] [Abstract][Full Text] [Related]
9. The Role of Compounds Derived from Natural Supplement as Anticancer Agents in Renal Cell Carcinoma: A Review.
Haque I; Subramanian A; Huang CH; Godwin AK; Van Veldhuizen PJ; Banerjee S; Banerjee SK
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29301217
[TBL] [Abstract][Full Text] [Related]
10. The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma.
Bilen MA; Carlisle JW; Sonpavde G
Expert Opin Investig Drugs; 2018 Feb; 27(2):163-170. PubMed ID: 29323560
[TBL] [Abstract][Full Text] [Related]
11. Renal cell carcinoma therapy: Current and new drug candidates.
Pontes O; Oliveira-Pinto S; Baltazar F; Costa M
Drug Discov Today; 2022 Jan; 27(1):304-314. PubMed ID: 34265458
[TBL] [Abstract][Full Text] [Related]
12. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.
Jeong DE; Song HJ; Lim S; Lee SJ; Lim JE; Nam DH; Joo KM; Jeong BC; Jeon SS; Choi HY; Lee HW
Oncotarget; 2015 Oct; 6(32):33046-64. PubMed ID: 26426994
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-451 regulates chemoresistance in renal cell carcinoma by targeting ATF-2 gene.
Sun X; Lou L; Zhong K; Wan L
Exp Biol Med (Maywood); 2017 Jun; 242(12):1299-1305. PubMed ID: 28429654
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived xenograft models to optimize kidney cancer therapies.
Patel A; Cohen S; Moret R; Maresh G; Gobe GC; Li L
Transl Androl Urol; 2019 May; 8(Suppl 2):S156-S165. PubMed ID: 31236333
[TBL] [Abstract][Full Text] [Related]
15. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH
PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627
[TBL] [Abstract][Full Text] [Related]
16. An Overview of Renal Cell Carcinoma Hallmarks, Drug Resistance, and Adjuvant Therapies.
DA Silva Prade J; DE Souza RS; DA Silva D'Αvila CM; DA Silva TC; Livinalli IC; Bertoncelli ACZ; Saccol FK; DE Oliveira Mendes T; Wenning LG; DA Rosa Salles T; Rhoden CRB; Cadona FC
Cancer Diagn Progn; 2023; 3(6):616-634. PubMed ID: 37927802
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC.
Pal K; Madamsetty VS; Dutta SK; Mukhopadhyay D
Int J Nanomedicine; 2019; 14():5109-5123. PubMed ID: 31371950
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation.
Yun EJ; Lin CJ; Dang A; Hernandez E; Guo J; Chen WM; Allison J; Kim N; Kapur P; Brugarolas J; Wu K; He D; Lai CH; Lin H; Saha D; Baek ST; Chen BPC; Hsieh JT
Clin Cancer Res; 2019 Jul; 25(14):4542-4551. PubMed ID: 31000589
[TBL] [Abstract][Full Text] [Related]
19. Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities.
Pohl L; Friedhoff J; Jurcic C; Teroerde M; Schindler I; Strepi K; Schneider F; Kaczorowski A; Hohenfellner M; Duensing A; Duensing S
Front Oncol; 2022; 12():889686. PubMed ID: 35619925
[TBL] [Abstract][Full Text] [Related]
20. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
Jedeszko C; Paez-Ribes M; Di Desidero T; Man S; Lee CR; Xu P; Bjarnason GA; Bocci G; Kerbel RS
Sci Transl Med; 2015 Apr; 7(282):282ra50. PubMed ID: 25855496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
